Current Assets
Accounts Receivable
Amgen Accounts Receivable decreased by 4.5% to $9.14B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.4%, from $8.13B to $9.14B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 16.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase relative to sales may signal collection issues or aggressive revenue recognition, while a decrease suggests efficient cash conversion.
Detailed definition
The balance of payments owed to the company by customers for goods or services delivered, adjusted for an allowance for...
Peer comparison
Common in pharmaceutical and biotech sectors; peers are evaluated on Days Sales Outstanding (DSO).
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.48B | $4.77B | $4.9B | $5.08B | $5.33B | $5.33B | $5.56B | $5.74B | $5.83B | $6.15B | $7.27B | $6.78B | $6.93B | $7.32B | $6.78B | $8.13B | $8.7B | $8.49B | $9.57B | $9.14B |
| QoQ Change | — | +6.4% | +2.7% | +3.7% | +4.9% | -0.0% | +4.4% | +3.1% | +1.6% | +5.4% | +18.3% | -6.8% | +2.3% | +5.5% | -7.3% | +19.9% | +7.0% | -2.4% | +12.7% | -4.5% |
| YoY Change | — | — | — | — | +18.9% | +11.8% | +13.6% | +13.0% | +9.4% | +15.4% | +30.6% | +18.1% | +18.9% | +19.1% | -6.7% | +20.0% | +25.5% | +16.0% | +41.1% | +12.4% |
Range$4.48B – $9.57B
CAGR+16.2%
Avg YoY Growth+17.3%
Median YoY Growth+17.1%
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Amgen's accounts receivable?
- Amgen (AMGN) reported accounts receivable of $9.14B in Q1 2026.
- How has Amgen's accounts receivable changed year-over-year?
- Amgen's accounts receivable increased by 12.4% year-over-year, from $8.13B to $9.14B.
- What is the long-term trend for Amgen's accounts receivable?
- Over 5 years (2020 to 2025), Amgen's accounts receivable has grown at a 16.2% compound annual growth rate (CAGR), from $4.53B to $9.57B.
- What does accounts receivable mean?
- Money owed to the company by customers for products already delivered.